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Abstract
Pathological angiogenesis contributes to cancer progression and
chronic inflammatory diseases. In inflammatory bowel disease, the
microvasculature expands by intussusceptive angiogenesis (IA), a
poorly characterized mechanism involving increased blood flow and
splitting of pre-existing capillaries. In this report, mice lacking the
protease MT1-MMP in endothelial cells (MT1iDEC) presented limited
IA in the capillary plexus of the colon mucosa assessed by 3D imag-
ing during 1% DSS-induced colitis. This resulted in better tissue
perfusion, preserved intestinal morphology, and milder disease
activity index. Combined in vivo intravital microscopy and lentiviral
rescue experiments with in vitro cell culture demonstrated that
MT1-MMP activity in endothelial cells is required for vasodilation
and IA, as well as for nitric oxide production via binding of the C-
terminal fragment of MT1-MMP substrate thrombospondin-1 (TSP1)
to CD47/avb3 integrin. Moreover, TSP1 levels were significantly
higher in serum from IBD patients and in vivo administration of an
anti-MT1-MMP inhibitory antibody or a nonamer peptide spanning
the avb3 integrin binding site in TSP1 reduced IA during mouse coli-
tis. Our results identify MT1-MMP as a new actor in inflammatory IA
and a promising therapeutic target for inflammatory bowel disease.
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Introduction
The vasculature delivers oxygen and nutrients to all tissues and
must constantly and dynamically adapt to tissue needs. Angiogene-
sis, the formation of new capillaries from pre-existing vessels, is
required to expand the vasculature not only during development
and tissue repair, but also in pathological conditions such as cancer
and chronic inflammatory disease (Potente et al, 2011). In these
contexts, the newly formed vasculature is often marginally func-
tional and leaky, contributing to disease progression (De Bock et al,
2011; Parma et al, 2017). Angiogenesis often occurs by capillary
sprouting, which is mainly triggered by hypoxia and the subsequent
production of vascular endothelial growth factor (VEGF). New ther-
apeutic interventions in cancer and other diseases have therefore
focused on inhibiting sprouting angiogenesis, mostly by blocking
VEGF (Potente et al, 2011). However, the development of resistance
to this approach and its overall limited success have shifted atten-
tion to the possible existence of alternative modes of capillary
expansion (Ribatti & Djonov, 2012).
Intussusceptive angiogenesis (IA) was formally recognized in the
1980s and involves the expansion of the microvasculature through
the formation of intraluminal pillars, eventually resulting in capil-
lary splitting (Burri et al, 2004). IA contributes to the physiological
expansion of capillary beds during embryonic development and
postnatal coronary vasculature remodeling (van Groningen et al,
1991; Djonov et al, 2000). IA also occurs in certain cancers and
chronic diseases such as bronchopulmonary dysplasia, in which IA
generates an aberrant and dysfunctional vasculature that may
contribute to disease progression (Ribatti & Djonov, 2012; Giaco-
mini et al, 2015; De Paepe et al, 2017). Sprouting and intussuscep-
tion angiogenesis mechanisms can co-exist in pathophysiological
settings (Konerding et al, 2012; Karthik et al, 2018).
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IA is a dynamic, fast, and metabolically undemanding process
that barely involves proliferation but instead progresses through
intraluminal endothelial cell rearrangements (Burri et al, 2004). IA
is usually driven by a persistent increase in blood flow, and it aimed
to restore shear stress in the split vessels (Styp-Rekowska et al,
2011). However, knowledge is scarce about the cellular and molecu-
lar mechanisms underlying IA. This is partly due to the absence of
in vitro models of IA and the limited experimental techniques to
identify and quantify genuine IA events in vivo, apart from scanning
electron microscopy and corrosion casts (Nowak-Sliwinska et al,
2018). Nevertheless, genes whose expression is enriched during IA
have been identified in skeletal muscle, in which the vasodilator
prazosin induces IA and the excision of the agonist muscle, sprout-
ing angiogenesis (Zhou et al, 1998; Egginton, 2011). Upregulated
genes in skeletal muscle of prazosin-treated mice included endothe-
lial nitric oxide synthase (eNOS) and neuropilin-1 (Nrp1), suggest-
ing a role for these pathways in IA. Analysis of eNOS (Nos3)-
deficient mice confirmed that eNOS is required for IA but not for
sprouting angiogenesis in skeletal muscle (Williams et al, 2006);
more recently, nitric oxide (NO) has been shown to contribute to
pathological IA in tumors (Vimalraj et al, 2018). Advanced micro-
scopy techniques and increasing knowledge about endothelial cell
responses to blood flow have together favored the recent characteri-
zation of the IA modulators endoglin and ephrinB2/EphB4 (Hlush-
chuk et al, 2017; Groppa et al, 2018). However, it remains unclear
how these pathways are regulated and contribute to IA, particularly
during disease.
IA is the mechanism of capillary expansion during intestinal
inflammation, and analysis of chemically induced murine colitis
(e.g., with dextran sodium sulfate; DSS) has advanced knowledge
about the morphogenesis and hemodynamics underlying inflamma-
tory IA (Mori et al, 2005; Ravnic et al, 2007; Filipovic et al, 2009;
Konerding et al, 2010). These studies show that mechanical forces
and changes in intraluminal blood flow drive IA and that a marked
vasodilation occurs during the first stages of IA during colitis, before
complete duplication of the mucosal plexus (Filipovic et al, 2009;
Konerding et al, 2010). The DSS mouse model of colitis recapitu-
lates some of the features of human inflammatory bowel disease
(IBD), a chronic inflammatory disease of the intestine comprising
ulcerative colitis and Crohn’s disease and characterized by phases
of remission and relapse (Podolsky, 2002). IBD is a multifactorial
disease featuring a primary defect in intestinal epithelial barrier
integrity and an exacerbated immune response to the microbiota
and for which there is as yet no universal and efficient therapy
(Gyires et al, 2014). As in other chronic inflammatory diseases, coli-
tis progression is believed to involve angiogenesis, which is there-
fore regarded as a potential treatment target for human IBD
(Chidlow et al, 2006; Koutroubakis et al, 2006; Danese, 2007).
Attempts have been made to reduce angiogenesis and reduce colitis
symptoms by targeting diverse molecular pathways, such as VEGF,
TSP1/CD36, and CD40-CD40L, with limited success (Danese et al,
2007a,b; Punekar et al, 2008; Scaldaferri et al, 2009). There is there-
fore a need to decipher the molecular pathways involved in colitis-
associated IA in order to design more rational therapeutic strategies.
During colitis, epithelial and mesenchymal cells, as well as other
cell types, increase expression of MT1-MMP (Pender et al, 2000; te
Velde et al, 2007; Alvarado et al, 2008), a membrane-anchored
matrix metalloproteinase whose activity contributes to sprouting
angiogenesis in vitro and in vivo through the combined processing
of substrates such as TSP1, NID1, and CYR61 (Galvez et al, 2001,
2005; Koziol et al, 2012a). MT1-MMP also has non-proteolytic
actions that contribute to the regulation of Rac1 or HIF1a signaling
(Koziol et al, 2012b). MT1-MMP is expressed in endothelial cells
(ECs) at low levels in homeostatic conditions, but it is upregulated
by the pro-inflammatory cytokines TNFa and interleukin-1 (Rajava-
shisth et al, 1999; Koziol et al, 2012a). Despite the important role of
MT1-MMP in sprouting angiogenesis, the potential contribution of
endothelial MT1-MMP to IA, particularly in the context of inflamma-
tion and IBD, has not been explored previously.
In the present study, the analysis of mice specifically lacking
MT1-MMP in ECs identified this protease as an actor in inflamma-
tion-driven IA whose endothelial targeting results in preserved
vasculature and amelioration of colitis. Deciphering the underlying
MT1-MMP/TSP1/avb3 integrin/NO molecular axis opens avenues
for the development of new diagnostic and therapeutic interventions
in IBD.
Results
MT1-MMP is required for intussusceptive angiogenesis (IA) in
DSS-induced colitis
To investigate the possible role of MT1-MMP (gene name MMP14)
in inflammation-driven IA, we used the DSS-induced colitis model,
a widely recognized model of IA (Konerding et al, 2010). We first
assessed MT1-MMP expression in ECs of the mucosa vasculature in
the colon by tracking b-gal expression in MT1lacZ/+ reporter mice.
In non-treated mice, nuclear b-gal expression was present in ECs in
the vessels nearby the muscularis mucosa but was barely detected
in those of the mucosal plexus, the polygonal capillary network
around the colonic crypts. Treatment of mice with 1% DSS signifi-
cantly increased the proportion of endothelial cells expressing b-gal
in the mucosal plexus after 3 days with a remaining augmented
trend at 7 days (Appendix Fig S1A and B). Patches of b-gal-positive
ECs were frequently detected near the Y-junctions (tri-corners) in
the mucosal vascular plexus (Appendix Fig S1C). MT1-MMP was
deleted in the ECs of MT1-MMPf/f;Cdh5CreERT2 mice (MT1iDEC) mice
by daily injections of 4-hydroxy-tamoxifen (4-OHT) for 5 days; 4-
OHT injections began 3 days before DSS treatment. Isolated lung
ECs were examined to confirm efficient recombination of the floxed
Mmp14 allele and the absence of MT1-MMP mRNA (Fig EV1A–C).
MT1-MMP expression was also reduced in the colonic capillaries
from MT1iDEC mice examined at 7 days post-DSS (Fig EV1D).
To test the effect of prophylactic endothelial MT1-MMP deletion
on DSS-induced IA, we implemented a 3D imaging method based on
high-resolution confocal microscopy and Imaris image analysis of
whole-mount CD31-stained mouse intestine; this method allowed us
to quantify holes in the vascular tri-corners indicating intraluminal
pillars as well as capillary loops and duplications in the mucosal
plexus, all hallmarks of IA (Fig EV2A). We also measured capillary
bifurcation angles in the mucosal plexus, which decrease during IA
(Fig EV2B; Ackermann et al, 2013). DSS-induced mild colitis in
MT1f/f;Cdh5CreERT2-negative (MT1f/f) control mice was associated
with significantly increased IA events (holes, loops, and duplica-
tions) and smaller capillary bifurcation angles at 3 days compared
2 of 22 EMBO Molecular Medicine 12: e10862 | 2020 ª 2019 The Authors
EMBO Molecular Medicine Sergio Esteban et al
with non-treated mice (Fig 1A–C). Of note, MT1iDEC mice showed
significantly reduced numbers of DSS-induced IA capillary events
(holes, loops, and duplications) at 3 and 7 days compared with
MT1f/f mice (Fig 1A and B); intercapillary angles were also
preserved in the colon mucosal plexus of MT1iDEC mice at 3 days
post-DSS treatment (Fig 1C). These findings identify MT1-MMP as a
novel endothelial actor in inflammatory IA.
Loss of endothelial MT1-MMP preserves intestinal vascular
perfusion and ameliorates colitis
To investigate the impact of inflammatory IA on vascular function,
we analyzed vessel perfusion by intravascular injection of isolectin
B4 (IB4). Perfusion decreased during colitis progression in the
mucosa vascular plexus of both MT1f/f and MT1iDEC mice, but it
was significantly better preserved in the latter at 7 days post-1%
DSS treatment (Fig 2A and B). Furthermore, 1% DSS induced vascu-
lar leakage at days 3 and 7 in the colonic mucosa of MT1f/f mice
and at a lower extent in MT1iDEC mice (Appendix Fig S2A).
Treatment with 1% DSS produced only subtle alterations in the
intestinal mucosa after 3 days, but at 7 days, hematoxylin and eosin
histology revealed better preservation of colon morphology in
MT1iDEC mice, showing fewer areas of crypt destruction than control
mice (Fig 2C). Second-harmonic generation (SHG) microscopy con-
firmed the presence of well-structured collagen fibers surrounding
crypts in MT1iDEC mice at 7 days post-DSS, contrasting with abun-
dant and disorganized collagen fibers in control mice (Fig 2D), an
additional sign of enhanced tissue damage and fibrosis. To estimate
disease severity over the 7 days of 1% DSS treatment, we calculated
the disease activity index (DAI), based on a composite of weight
loss, stool consistency, and hemorrhage (see Methods). The DAI
was significantly lower in MT1iDEC mice than in MT1f/f controls
A B
C
Figure 1. MT1-MMP expression in endothelial cells contributes to intussusceptive angiogenesis in colitis.
A Representative maximum-intensity projection images of colon mucosal plexus in CD31-stained (green) whole-mount distal colon from MT1f/f and MT1iDEC mice left
untreated (basal) or treated with 1% DSS for 3 or 7 days. Scale bar, 40 lm. Arrows, arrowheads, and asterisks indicate duplications, loops, and pillars, respectively.
B Quantification of IA events in the colon mucosal plexus of mice treated as in (A), including vascular holes, duplications, and loops; n = 9–15 mice per genotype and
condition. Data are shown as mean  SEM and were tested by one-way ANOVA with Benjamini and Hochberg post-test; *P < 0.05, **P < 0.01.
C Quantification of vascular angles at the Y-junctions in the colon mucosal plexus of mice left untreated or treated with 1% DSS for 3 days; n = 6 mice per genotype
and condition. Data are shown as mean  SEM and additionally as individual animal values and were tested by one-way ANOVA with Benjamini and Hochberg
post-test; **P < 0.01.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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from DSS day 5 onward, indicating milder disease in the absence of
endothelial MT1-MMP (Fig 2E). Numbers of CD11b+ leukocytes
(mostly neutrophils and monocytes) did not differ between geno-
types at DSS day 3, when IA was already decreased in MT1iDEC
mice; in contrast, at DSS day 7, CD11b+ leukocyte numbers in
MT1iDEC mice showed a slight but significant reduction compared
with MT1f/f controls (Appendix Fig S2B and C). Thus, endothelium-
specific MT1-MMP deletion improves 1% DSS-induced colitis
progression primarily through an early impact on IA events at
3 days rather than on vascular perfusion, leukocyte traffic, and
tissue alterations modulated at 7 days.
In light of these results, we next tested the therapeutic action of
endothelial MT1-MMP deletion on colitis progression. Mice received
five daily 4-OHT injections beginning 4 days after the initiation of
1% DSS treatment, and mice were sacrificed at DSS day 15. Thera-
peutic endothelial MT1-MMP deletion during established colitis
significantly reduced weight loss and DAI from day 9 onward
compared with MT1f/f control mice (Fig EV3).
MT1-MMP expression in ECs is required for vasodilation and
NO production
The cellular and molecular mechanisms underlying IA are poorly
defined, but there is a general consensus that it is initiated by
changes in hemodynamic forces and increased blood flow (Filipovic
et al, 2009). To investigate the role of endothelial MT1-MMP in this
early step of IA that involves vasodilation (Fig 3A), we relied on
intravital microscopy of the cremaster muscle and monitored arteri-
ole vasodilation by injecting acetylcholine (ACh), which triggers EC
NO secretion (Rius & Sanz, 2015; Fig 3B–D). No differences between
genotypes were observed in arteriole diameter (~ 30 lm) at baseline
(Fig 3C, and Movies EV1 and EV2); in contrast, maximal Ach-
induced vasodilation (reached 3 min after injection) was signifi-
cantly impaired in arterioles of MT1iDEC mice compared with MT1f/f
controls (Fig 3D, and Movies EV1 and EV2). Given the observation
of IA events in colon mucosal plexus capillaries, we also analyzed
the capillaries in the cremaster muscle. The diameter of cremaster
capillaries did not increase in MT1iDEC mice after Ach injection;
however, this impaired response was rescued by i.v. injection of the
NO donor DEANO (Fig 3E and F). These results suggest that
impaired vasodilation in MT1-MMP-null ECs may be due to
decreased NO production. Low NO production was confirmed by
DAF-FM analysis of aortic endothelial cells (MAEC) isolated from
MT1iDEC mice (Appendix Fig S3). Furthermore, human umbilical
vein endothelial cells (HUVEC) expressing MT1-MMP-targeting
siRNA (siMT1) not only produced significantly lower amounts of
NO (Fig 4A) but also expressed lower amounts of eNOS protein and
eNOS (Nos3) mRNA than corresponding control ECs (Fig 4B–D).
We next implemented a protocol to assess VEGF-induced vasodi-
lation of the colon mucosal plexus by its administration via a rectal
cannula to get closer to the pathophysiology of IA during colitis
(Fig EV4A and B). As shown in Fig EV4C and D, the diameter of the
mucosa plexus capillaries was significantly reduced in VEGF-treated
MT1iDEC mice compared to MT1f/f controls.
MT1-MMP catalytic activity is required for NO production and
colitis-induced IA
To determine whether inflammatory IA regulation by MT1-MMP
depends on its catalytic or signaling activities (Gonzalo et al, 2010;
Koziol et al, 2012a), MT1f/f;Cdh5CreERT2 mice were inoculated with
lentivirus (LV) encoding full-length (FL) MT1-MMP or mutated
versions that abolish its catalytic (E240A) or signaling (Y573F)
activities. Daily 4-OHT injections to delete endogenous endothelial
MT1-MMP were started 72 h after LV injection, and 1% DSS treat-
ment was initiated 3 days later (Fig 5A and B). Western blot analy-
sis of GFP expression confirmed similar transduction levels in the
colon regardless of the injected LV (Fig 5C). LV encoding FL and
Y573F MT1-MMP increased IA events 3 days post-DSS to levels
comparable to those observed in LV-mock-injected MT1f/f mice,
whereas LV encoding E240A MT1-MMP had no effect and injected
mice showed similar numbers of IA events than LV-mock-injected
MT1iDEC mice (Fig 5D–F). These results demonstrate that IA induced
by 1% DSS colitis requires the catalytic activity of MT1-MMP.
MT1-MMP cleavage of TSP1 drives EC NO production
We next tested the effect of the inhibitory antibody anti-MT1-MMP
LEM-2/15 (Galvez et al, 2001) on NO production. The inhibitory
LEM-2/15 antibody significantly reduced NO amount in HUVEC
transfected with control siRNA (siControl) in comparison with non-
treated or isotype control-treated cells, whereas the antibody had no
effect on NO production by siMT1-silenced HUVEC (Appendix Fig
S4A). MT1-MMP catalytic activity is thus also required for EC
NO production, which likely acts upstream of inflammatory IA
(Williams et al, 2006).
◀ Figure 2. MT1-MMP absence from endothelial cells limits deterioration of vascular perfusion and impedes colitis progression.A Representative maximum-intensity projection images of whole-mount distal colons stained for CD31 (green) and IB4 (red) in MT1f/f and MT1iDEC mice left untreated
(basal) or treated with 1% DSS for 3 or 7 days. Scale bar, 40 lm.
B Perfusion decreased during 1% DSS-induced colitis in MT1f/f and MT1iDEC mice; n = 8–12 mice per genotype and condition. Data are shown as mean  SEM and
were tested by one-way ANOVA with Benjamini and Hochberg post-test; **P < 0.01.
C Representative H&E-stained colon sections from MT1f/f and MT1iDEC mice left untreated (basal) or treated with 1% DSS for 3 or 7 days. Arrows indicate crypt
destruction. Scale bar, 50 lm.
D Representative second-harmonic generation (SHG) microscopy images of mucosal plexus in whole-mount colons from MT1f/f or MT1iDEC mice left untreated (basal) or
treated with 1% DSS for 3 or 7 days. Scale bar, 40 lm.
E Disease activity index (DAI, a composite of weight change, stool consistency, and presence of fecal blood) during 1% DSS-induced colitis in MT1f/f and MT1iDEC mice.
Untreated mice were included as a control. n = 19–24 per genotype and condition. Data are shown as mean  SEM and were tested by two-way ANOVA with
Benjamini and Hochberg post-test; ***P < 0.001.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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Figure 3. Endothelial cell MT1-MMP expression is required for nitric oxide-dependent vasodilation in vivo.
A Scheme showing IA process including vasodilatation, pillar formation, and vascular splitting. EC, endothelial cell.
B Representative intravital microscopy images of cremaster muscle from MT1f/f or MT1iDEC mice before and 15 min after i.v. injection of 100 ll of 100 lM
acetylcholine (ACh). A and V mark arterioles and venules, respectively, and yellow arrows indicate arteriole diameter. Elapsed time is designated as hh:mm. Scale
bar, 30 lm.
C, D Cremaster arteriole diameter in basal conditions (C) and the maximum vasodilation response (diameter fold change) after 3 min of ACh stimulation (D); n = 5–6
mice per genotype. Data are shown as mean  SEM and were tested by paired t-test; **P < 0.01.
E Representative images of staining for CD31 (gray) in whole-mount cremaster muscle dissected from MT1f/f or MT1iDEC mice before and 15 min after i.v. injection of
100 ll of 100 lM ACh alone or in combination with DEANO (100 ll of 104 M). Scale bar, 25 lm.
F Quantification of capillary diameter in mice analyzed as in (E); n = 5–8 mice per genotype and condition. Data are shown as mean  SEM and were tested by
one-way ANOVA with Benjamini and Hochberg post-test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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Several angiogenesis pathways, including mechanisms involving
eNOS, are suppressed by the matricellular protein thrombospondin-
1 (TSP1) through its binding to CD36 (nM affinity) and/or CD47/
IAP (pM affinity) (Lawler & Lawler, 2012; Resovi et al, 2014). We
had previously identified TSP1 as a master MT1-MMP substrate and
showed that loss of MT1-MMP reduced TSP1 release in TNFa-
stimulated ECs (Koziol et al, 2012a). In the context of colitis, TSP1
serum levels increased after 7 days of 1% DSS treatment
(20.27  11.84 pg/ml in control vs. 37.04  1.21 pg/ml in treated
mice) and we sought to analyze the impact of endothelial MT1-
MMP in such release. For that, we examined TSP1 intestinal distri-
bution in DSS-treated mice, using an antibody against a sequence
near the TSP1 N-terminus (Lee et al, 2006). Immunostained sections
revealed that 1% DSS treatment upregulated TSP1 expression in the
mouse colon after 3 days (Fig 6A and B). Moreover, image analysis





Figure 4. Decreased nitric oxide production and eNOS expression in MT1-MMP-silenced human endothelial cells.
A Representative pseudo-colored microscopy images of DAF-FM (4-amino-5-methylamino-20 ,70-difluorofluorescein diacetate) fluorescence intensity in human
endothelial cells (HUVEC) expressing control or MT1-MMP siRNA (left); scale bar, 50 lm. The graph to the right shows DAF-FM mean fluorescence intensity (MFI)
values obtained in n = 637–879 cells analyzed per condition in six independent experiments. Data are shown as individual cell values and mean  SEM and were
tested by the Mann–Whitney test; ****P < 0.0001.
B, C Representative Western blot of eNOS and MT1-MMP in HUVEC expressing control or different MT1-MMP siRNAs; GAPDH is included as a loading control (B). Bar
graphs (C) show relative eNOS and MT1-MMP expression (vs. GAPDH); n = 5 independent experiments. Data are shown as mean  SEM and were tested by one-
sample t-test; ***P < 0.001, ****P < 0.0001.
D qPCR analysis of relative eNOS (NOS3) and MT1-MMP (MMP14) mRNA levels in HUVEC expressing control or MT1-MMP siRNAs; n = 4 independent experiments.
F.C., fold change. Data are shown as mean  SEM and were tested by one-sample t-test; ***P < 0.001, ****P < 0.0001.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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thick cuff around MT1-MMP-negative vessels of the colon mucosa
nearby the muscularis mucosa in MT1iDEC mice compared with less
TSP1 abundance around the MT1-MMP-expressing corresponding
vessels in MT1f/f mice (Fig 6B and C). These data indicate that
endothelial MT1-MMP contributes to perivascular TSP1 processing
in the intestine.
TSP1 also accumulated in siMT1-silenced HUVEC (Fig 7A),
related to defective TSP1 processing in the absence of the protease
(Koziol et al, 2012a). Moreover, culture on TSP1-coated plates
increased NO production in siControl-HUVEC significantly more
than in siMT1-silenced HUVEC, suggesting that signals mediated by
processed TSP1 contribute to increased NO production in MT1-
MMP-expressing ECs (Appendix Fig S4B). Accordingly, we detected
an N-terminal TSP1 fragment of about 50 KD in lysates from MT1-
MMP-expressing HUVEC whose abundance was reduced in MT1-
MMP-silenced cells, and we confirmed that TSP1 cleavage by the
MT1-MMP catalytic domain yielded that N-terminal fragment by
in vitro digestion assays (Fig EV5A and B). To decipher how MT1-
MMP-mediated TSP1 processing affects NO production, we
combined a CleavPredict search (Kumar et al, 2015) with in silico
protein modeling. This approach identified positions H441W and
P467Q in TSP1 as having good accessibility and proximity to the
protease catalytic pocket, suggesting them as candidate sites for
MT1-MMP cleavage (Appendix Table S1, and Fig EV5C and D), and
consistent with the N-terminal TSP1 fragment observed in HUVEC
lysates and by in vitro digestion (Fig EV5A and B). Moreover, the
amino acids flanking the predicted cleavage sites (P10:P1 positions)
had high MEROPS database scores (4:1 and 8:6 for H441W and P467Q
sites, respectively; https://www.ebi.ac.uk/merops/). Cleavage of
TSP1 by MT1-MMP at H441W and/or P467Q would likely disrupt the
CD36-binding motifs and generate a C-terminal fragment with
preserved binding sites for CD47/IAP and its partner avb3 integrin
(Lindberg et al, 1996), which would mediate MT1-MMP-dependent
NO production in ECs. To directly validate this hypothesis, we
investigated the effect of the E123CaG-1 human TSP1 fragment (aa
549–1,170; Margosio et al, 2008) spanning most of the predicted C-
terminal TSP1 fragment after MT1-MMP processing (441/467–
1,170) and containing CD47 and avb3 integrin binding sites. We
confirmed that the E123CaG-1 TSP1 fragment induced NO produc-
tion in MT1-MMP-deficient HUVEC compared with full-length TSP1
(Fig EV5E).
Interaction between CD47 and TSP1 influences NO signaling
(Rogers et al, 2014), and we found that an anti-CD47 antibody
known to block CD47 interaction with the C-terminal TSP1 domain
reduced NO production by MT1-expressing ECs but had no further
effect on NO production by siMT1-silenced HUVEC (Fig 7B). To
determine whether CD47-driven effects involve the activity of its
partner avb3 integrin, we blocked avb3 integrin binding to TSP1
with an inhibitory anti-av integrin antibody, an RGDS peptide, or
cilengitide (based on the cyclic peptide cyclo-RGDfV). All three
strategies significantly decreased NO production by MT1-expressing
ECs; in contrast, these treatments had negligible impact on the
already reduced NO production by siMT1-silenced cells (Fig 7B–D).
Similarly, NO production by siControl- and siMT1-transduced cells
was unaffected by the control peptide RADS or isotype control IgG.
The RGDS peptide can compete for avb3 integrin binding to several
matrix proteins; therefore, to test for a specific effect via TSP1, we
tested the effect on NO production by ECs of a selective nonamer
spanning the RGD binding site for avb3 integrin in TSP1. The
nonamer GDGRGDACK, but not the control peptide GDGRADACK,
reduced NO production in MT1-MMP-expressing endothelial cells
but not in siMT1-silenced cells (Fig 7E).
MT1-MMP/TSP1 signaling provides a possible diagnostic and
therapeutic target in IBD
To explore the possible implications of endothelial MT1-MMP-
mediated TSP1 processing in patients with IBD, we first checked
MT1-MMP and TSP1 vascular expression and distribution in unaf-
fected and affected colon areas of patients suffering from ulcerative
colitis or Crohn’s disease. Immunostaining on colon sections
revealed more abundant capillaries in affected vs. unaffected areas
that were accompanied by MT1-MMP and TSP1 upregulated expres-
sion and distinct tissue distribution; MT1-MMP was mainly located
in CD31-positive vessels of the inflamed intestine while TSP1 was
sparse around these vessels and mostly expressed by spiky cells
resembling macrophages (Fig 8A). Since TSP1 was stained with the
monoclonal antibody A6.1, which recognizes an epitope down-
stream of the predicted TSP1 cleavage sites for MT1-MMP (Annis
et al, 2006), this pattern is consistent with TSP1 cleavage by
endothelial MT1-MMP during DSS-induced colitis leading to TSP1
paucity around MT1-MMP-expressing vessels in MT1f/f mice (Fig 6B
and C) and to its release to the serum. We then quantified serum
TSP1 in a cohort of IBD patients scored for clinical activity, includ-
ing ≥ 50 patients with ulcerative colitis or with Crohn’s disease.
Remarkably, TSP1 was significantly more abundant in the serum
from patients with mildly active (but not with highly active) ulcera-
tive colitis or Crohn’s disease compared to healthy controls
◀ Figure 5. MT1-MMP actions in intussusceptive angiogenesis during colitis depend on its catalytic activity.A Lentivirus (LV) construct used to drive expression of MT1-MMP (MMP14) and green fluorescent protein (GFP) under the SFFV and IRES promoters, respectively. The
point mutations introduced to obtain the catalytic (E240A) and signaling (Y573F) mutants are indicated.
B Experimental design for i.v. lentiviral injection in mice and induction of mild colitis with 1% DSS.
C Western blot of GFP and MT1-MMP protein expression in colon lysates from MT1iDEC mice previously injected with mock LV or LV encoding full-length MT1-MMP
or the E240A or Y573F mutants; mice were sacrificed 3 days after 1% DSS treatment. Actin is included as a loading control.
D, E Representative maximum-intensity projection images of staining for CD31 (gray) in whole-mount colons from MT1f/f or MT1iDEC mice previously injected with mock
LV (D) or LV encoding full-length MT1-MMP or the E240A or Y573F mutants (E); mice were sacrificed 3 days after 1% DSS treatment. Scale bar, 40 lm. Arrows,
arrowheads, and asterisks indicate duplications, loops, and pillars, respectively.
F Quantification of IA events in mice treated as in (D and E); n = 5–8 mice per genotype and condition. Data are shown as mean  SEM and were tested by one-way
ANOVA with Benjamini and Hochberg post-test; *P < 0.05, **P < 0.01, ***P < 0.001.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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(Fig 8B). This finding thus suggests that serum TSP1 may be a
biomarker of early or mild IBD.
To evaluate the relevance of the MT1-MMP/TSP1/nitric oxide
pathway in colitis in vivo, we first injected intraperitoneally the C-
terminal E123CaG-1 TSP1 fragment (containing CD47 and avb3 inte-
grin binding sites) into MT1iDEC mice and observed that it signifi-
cantly increased the number of IA events 3 days post-1% DSS
treatment compared with mice treated with full-length TSP1
(Fig EV5F and G). Contrarily, blocking the generation of the TSP1
fragment by intraperitoneal injection of the anti-MT1-MMP inhibi-
tory antibody LEM-2/15 significantly decreased the number of IA
events in the mucosal plexus and conserved well-organized collagen
fibers in MT1f/f control mice after 3 days of 1% DSS treatment
compared to isotype control-treated mice (Fig 8C–E). Given our
A
B C
Figure 6. MT1-MMP absence in endothelial cells leads to perivascular accumulation of thrombospondin-1 (TSP1) in the inflamed colon.
A, B Representative maximum-intensity projection images of staining for TSP1 (red) and CD31 (gray) in (A) and also for MT1-MMP (green) in (B) in colon sections
obtained from MT1f/f and MT1iDEC mice left untreated (A) or treated with 1% DSS for 3 days (B). Magnified views are shown to the right. Scale bars, 100 lm in
main panels and 10 lm in the magnified views.
C TSP1 mean fluorescence intensity (MFI) in the perivascular area of large vessels present in the colon mucosa of treated mice, as depicted in (B); n = 4 mice per
genotype. Data are shown as mean  SEM and were tested by t-test; *P < 0.05.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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finding that avb3 integrin binding to TSP1 drives NO production in
ECs in vitro, we finally investigated the therapeutic potential of this
pathway by selectively blocking this interaction in vivo and
checking the impact on IA and colitis. MT1f/f control mice were fit-
ted with subcutaneous minipumps allowing continuous release of a





ª 2019 The Authors EMBO Molecular Medicine 12: e10862 | 2020 11 of 22
Sergio Esteban et al EMBO Molecular Medicine
GDGRADACK (equivalent dose of 2.4 mg/mouse/day). Mice were
then administered 1% DSS for 3 days, and colonic IA events were
analyzed after sacrifice. Mice treated with the TSP1-nonamer
GDGRGDACK had significantly fewer IA events than mice treated
with the control peptide (Fig 8F and G). The reduced IA in
GDGRGDACK-treated mice also resulted in better-preserved collagen
fiber organization assessed by second-SHG microscopy (Fig 8H).
Discussion
In this study, we identify the protease MT1-MMP as an endothelial
actor in IA, particularly during the pathogenesis of inflammatory
colitis. Our results point to NO production via an MT1-MMP/TSP1/
integrin avb3/eNOS pathway as the MT1-MMP catalytic-dependent
mechanism underlying vasodilation during this mode of angiogene-
sis (Fig 9). Evidence from human samples confirms that this path-
way is active in IBD, and blockade of DSS-induced colitis in mice
with an MT1-MMP inhibitory antibody or a TSP1-targeting peptide
indicates the potential of this strategy to improve IBD.
Our work also establishes that confocal microscopy of vessel-
stained whole-mount colons combined with 3D-image rendering
provides sufficient resolution to identify and quantify capillary
holes/pillars, loops, and duplications, all hallmarks of IA, circum-
venting the limitations of other techniques (Nowak-Sliwinska et al,
2018). The use of this imaging approach in fluorescent reporter
mouse lines may allow the detection of intraluminal pillars and
determination of the contribution of other cell types to pathophysio-
logical IA.
The EC-autonomous functions of MT1-MMP in vivo have
remained poorly defined due to the unavailability, until recently, of
conditionally deficient mice (Klose et al, 2013; Tang et al, 2013;
Gutierrez-Fernandez et al, 2015; Rafii et al, 2015). Our results
demonstrate that the specific absence of MT1-MMP in ECs decreases
the number of IA events early during 1% DSS-induced mild colitis
in mice and ameliorates the disease. These early IA events occur
when only a minor inflammatory infiltrate is present, suggesting
that the 1% DSS mild colitis model may be especially suited to
dissecting the vascular IA response independently of inflammation
(Chidlow et al, 2006). Our data also indicate that MT1-MMP
endothelial targeting could be useful in other conditions that involve
pathological IA, such as cancer (Ribatti & Djonov, 2012) and also
bronchopulmonary dysplasia of the pre-term lung, in light of the
reported role of MT1-MMP in postnatal lung expansion (De Paepe
et al, 2017; Oblander et al, 2005).
Regarding the mechanism by which MT1-MMP contributes to IA
and colitis, our results show that MT1-MMP EC deficiency results in
decreased NO-dependent vasodilation of cremaster muscle arterioles
and capillaries in vivo and establish that MT1-MMP catalytic activity
is required for NO production by ECs in vitro, regulating both eNOS
protein and mRNA levels. Our data therefore confirm a pathogenic
role for endothelial NO in colitis in line with Beck et al (Beck et al,
2004) and contrasting its reported healing and protection actions,
which are likely related to an impact on cell types other than the
endothelium (Sasaki et al, 2003; Aoi et al, 2008). The dependence
on endothelial MT1-MMP of colon mucosa capillary vasodilation
induced by VEGF, a driver of IA and recognized activator or nitric
oxide production (Cooke & Losordo, 2002), underscores the rele-
vance of this pathway in colitis pathophysiology.
MT1-MMP may play a dual, bimodal role via NO production
during IA initiation and progression. MT1-MMP-driven NO produc-
tion will primarily increase blood flow in the arterioles and therefore
in the downstream capillary plexus, promoting vessel splitting. This
is supported by the predominant constitutive expression of MT1-
MMP in arteriolar ECs rather than in the colonic mucosa capillaries.
But MT1-MMP is upregulated after DSS treatment in the ECs of the
mucosal plexus particularly near the Y-junctions where IA events
often occur. At these sites, blood flow gradients and decreased shear
stress lead to intraluminal pillar formation by undefined mecha-
nisms (Filipovic et al, 2009). MT1-MMP may also drive NO produc-
tion at these sites, which could then contribute to intraluminal EC
rearrangements and pillar formation. Accordingly, lack of NO
actions in the skeletal muscle led to reduced numbers of intralumi-
nal filopodia, ultimately hampering cell rearrangements needed for
capillary splitting (Williams et al, 2006). NO is also induced and
required during shear stress-driven angiogenesis (Kolluru et al,
2010) and can regulate EC junction remodeling and directional
migration (Noiri et al, 1998; Kevil et al, 2004; Thibeault et al, 2010;
Di Lorenzo et al, 2013). We previously showed that NO in turn
regulates MT1-MMP activity during EC migration (Genis et al,
2007), and our new findings thus define an additional layer of feed-
back NO regulation during this process.
MT1-MMP actions can rely on its catalytic or signaling capabili-
ties (Koziol et al, 2012b). Although we cannot exclude a
◀ Figure 7. Binding of TSP1 to CD47/IAP and avb3 integrin regulates nitric oxide production in MT1-MMP-expressing endothelial cells.A Representative maximum-intensity projection images of HUVEC expressing control or MT1-MMP siRNA and stained for MT1-MMP (gray), TSP1 (red), and F-actin
(phalloidin, green); nuclei are stained with Hoechst (blue). Scale bar, 20 lm.
B DAF-FM mean fluorescence intensity (MFI) in HUVEC expressing control or MT1-MMP siRNA and left untreated or treated with blocking anti-CD47 or anti-av integrin
antibodies (1 and 10 lg/ml, respectively, for 24 h) or their corresponding IgG isotype controls (IgG); n = 149–360 cells analyzed per condition in three independent
experiments.
C DAF-FM mean fluorescence intensity (MFI) in HUVEC expressing control or MT1-MMP siRNA and left untreated or treated with 2 nM or 200 lM RGDS or its control
peptide RADS; n = 147–385 cells analyzed per condition in three independent experiments.
D DAF-FM mean fluorescence intensity (MFI) in HUVEC expressing control or MT1-MMP siRNA and left untreated or treated with 2 nM or 20 lM of the RGD cyclic
peptide cilengitide; n = 100–360 cells analyzed per condition in three independent experiments.
E DAF-FM mean fluorescence intensity (MFI) in HUVEC expressing control or MT1-MMP siRNA and left untreated or treated with 2 nM or 200 lM of the nonamer
GDGRGDACK or its control peptide GDGRADACK; n = 149–337 cells analyzed per condition in three independent experiments.
Data information: Data are shown in all panels as individual cell values and mean  SEM and were tested by the Kruskal–Wallis test; ****P < 0.0001, ####P < 0.0001.
* indicates comparison with Ctrl-siRNA, and # indicates comparison of the condition with its corresponding control. Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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contribution to IA through mechanisms involving regulation of Rac1
signaling activity (Gonzalo et al, 2010), the lentivirus in vivo rescue
experiments indicate the involvement of MT1-MMP catalytic activ-
ity. Our earlier work identified TSP1 as the master substrate nucleat-
ing the combinatorial proteolytic MT1-MMP program related to EC
migration, invasion, and vessel formation in endothelial cells stimu-
lated with TNFa (Koziol et al, 2012a), a crucial cytokine during coli-
tis progression (Danese, 2008). TSP1 is a pleiotropic matricellular
protein widely recognized as an inhibitor of angiogenesis, although
certain domains can stimulate ECs (Armstrong & Bornstein, 2003).
TSP1 is therefore considered a promising target in cancer and
inflammatory and vascular diseases, and agonist and antagonist
peptide sequences and domains have been trialed in animal models
(Taraboletti et al, 2010; Lopez-Ramirez et al, 2017). TSP1 expres-
sion has been reported in the context of vascular expansion by IA,
for example, in the chorioallantoid membrane and during colitis;
trials of the TSP1 mimetic octapeptide ABT-898 in the mouse colitis
model showed a partial decrease in microvascular density (Gutier-
rez et al, 2015). Nevertheless, to our knowledge, the role of TSP1 in
IA, particularly in the inflammatory context, has not yet been
directly assessed.
Interaction of TSP1 with CD36 via its type I repeat and with
CD47 via its C-terminal globular domain inhibits NO signaling
through several mechanisms (Isenberg et al, 2008a). Our data reveal
that TSP1 processing by MT1-MMP contributes to NO production.
Cleavage of TSP1 by MT1-MMP might disturb CD36 binding and
unbrake its NO inhibition (Isenberg et al, 2009). However, work
from Iruela-Arispe’s group on TSP1 processing by Adamts1 during
wound healing predicts that the cleaved N-terminal TSP1 fragment
will be unstable, whereas the C-terminal fragment (able to bind
CD47/avb3 integrin) can remain in the inflamed tissue and be
released to the serum (Lee et al, 2006). Our results confirm the pres-
ence of TSP1 in the serum of both mice and patients affected by coli-
tis. Moreover, we demonstrated that NO production is induced by
the C-terminal TSP1 fragment in MT1-MMP-deficient ECs, and
contrarily, it is reduced in MT1-MMP-expressing ECs by inhibiting
the interaction of TSP1 with avb3 integrin or CD47 (Isenberg et al,
2008b), which is known to associate with and regulate b3 integrin
(Chung et al, 1997). Our data indicate that MT1-MMP-mediated
cleavage of TSP1 releases TSP1 fragments from the matrix, allowing
their interaction with the CD47/avb3 integrin complex likely active
at the dorsal plasma membrane (Lindberg et al, 1996). Our results
also identify for the first time that interaction of avb3 integrin with
the RGD sequence in TSP1 is crucial to the induction of NO produc-
tion in vitro and inflammatory IA in vivo. avb3 integrin has long
been recognized as a crucial regulator of vascular development and
angiogenesis, with fine-tuned actions depending on the initial status
of the vasculature and/or the accompanying molecular microenvi-
ronment, similar to the dual actions described for TSP1 (Armstrong
& Bornstein, 2003; Robinson & Hodivala-Dilke, 2011). Danese and
coworkers previously showed that treatment with the non-RGD-
based peptide ATN161, which blocks both avb3 and a5b1 integrins,
effectively decreased angiogenesis and improved colitis in the IL-
10/ mouse model but not in the DSS-induced model (Danese
et al, 2007a). Our study supports integrin specificity, demonstrating
that avb3 integrin binding to TSP1 drives NO production in vitro
and IA in vivo. This is likely related to the induction of selective
signals by avb3 but not b1 integrins (Leavesley et al, 1993;
Yurdagul et al, 2013). Whether TSP1 interactions with other recep-
tors in ECs (such as calcium channels) play additional roles in NO
production will require further research (Resovi et al, 2014; Risher
et al, 2018). We propose that the proteolytic processing of TSP1
enables pleiotropic actions (Iruela-Arispe, 2008). Upregulated MT1-
MMP and TSP1 expression in inflammation, vascular disease, and
cancer will favor cleaved TSP1-avb3 integrin interaction, NO
production, and IA in preference to TSP1-CD36 binding, macro-
phage recruitment, and inflammation (Lopez-Dee et al, 2011). Since
ECs express low levels of MT1-MMP and TSP1 under homeostatic
conditions, the upregulation of endothelial MT1-MMP and thus
TSP1 processing in specific disease settings may account for the
reported dose or cell-type-dependent dual actions of TSP1 on NO
and inflammation (Armstrong & Bornstein, 2003).
Although promotion of lymphangiogenesis by VEGF-C seems a
promising strategy for colitis alleviation in mouse models
◀ Figure 8. The MT1-MMP/TSP1/avb3 integrin pathway is a potential biomarker and therapeutic target in inflammatory bowel disease.A Representative maximum-intensity projection images of staining for CD31 (green), MT1-MMP or TSP1 (red), and Hoechst (blue, nuclei) in colon sections obtained
from an IBD patient. Boxed areas are shown in magnified views below with merged images of green and red channels in the middle and single channels to the
bottom. Non-affected and affected mucosa areas from the same patient are shown for comparison. Scale bar, 50 lm (upper panel) and 20 lm (magnified views). V,
vessel.
B ELISA analysis of serum TSP1 in healthy individuals and patients affected by ulcerative colitis (left) or Crohn’s disease (right). n = 12–37 individuals per condition. LA
and HA indicate patients with low and high active disease based on clinical score. Data are shown as individual values and mean  SEM and were tested by one-
way ANOVA with Benjamini and Hochberg post-test; ***P < 0.001.
C Representative maximum-intensity projection images of CD31 staining (green) in whole-mount colon mucosal plexus of MT1f/f mice injected intraperitoneally with
3 mg/kg of the anti-MT1-MMP inhibitory antibody LEM-2/15 or its isotype control at day 0 and day 2 during the 3 days of treatment with 1% DSS. Scale bar, 40 lm.
Arrows, arrowheads, and asterisks indicate duplications, loops, and pillars, respectively.
D Quantification of IA events in mice treated as in (C); n = 8 mice per condition in two independent experiments. Data are shown as mean  SEM and were tested by
t-test; **P < 0.01.
E Representative second-harmonic generation (SHG) microscopy images of whole-mount colons from MT1f/f mice treated as in (C). Scale bar, 40 lm.
F Representative maximum-intensity projection images of CD31 staining (green) in whole-mount colon mucosal plexus of MT1f/f mice treated with the TSP1 nonamer
GDGRGDACK or its control peptide GDGRADACK by continuous minipump delivery (up to 2.4 mg/mouse/day) for 3 days during 1% DSS treatment. Scale bar, 40 lm.
Arrows, arrowheads, and asterisks indicate duplications, loops, and pillars, respectively. Mice/n independent experiments.
G Quantification of IA events in mice treated as in (F); n = 5 and 6 mice per condition in two independent experiments. Data are shown as mean  SEM and were
tested by t-test; *P < 0.05.
H Representative second-harmonic generation (SHG) microscopy images of whole-mount colons from MT1f/f mice treated as in (F). Scale bar, 40 lm.
Data information: Please see Appendix Table S3 for exact P-values.
Source data are available online for this figure.
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(D’Alessio et al, 2014), there is still no proven benefit for IBD
patients of targeting angiogenesis, whether indirectly (inhibiting
the immune response) or directly (inhibiting VEGF or other angio-
genic molecules as TNFa) (Chidlow et al, 2006; Eder et al, 2015).
In this regard, conflicting effects have been reported for VEGF inhi-
bition in colitis, likely related to the kinetics and efficiency of its
targeting (Tolstanova et al, 2009; Chernoguz et al, 2012). This
controversy underlines the need to deepen our understanding of
the mechanisms underlying IA in IBD for a more rational design of
angiogenesis inhibitors. Our findings identify the MT1-MMP/TSP1/
avb3 integrin/NO pathway as a possible therapeutic target for IA
and colitis since blocking this axis by inhibiting MT1-MMP activity
or competing TSP1 binding to avb3 integrin both diminished IA
and preserved collagen fiber organization. Moreover, the in silico
docking of the TSP1 cleavage sites with MT1-MMP could permit
small-molecule screening and buildup to cell-specific strategies
involving peptide-directed delivery, nanoparticles, or other modes of
tissue-tailored therapeutic intervention. It is remarkable that the
elevated serum TSP1 detected in patients with low-activity colitis,
but not high-activity disease, correlated with the protection
conferred by MT1-MMP endothelial deletion in mild mouse colitis
but not severe disease (not shown). This suggests that the MT1-
MMP/TSP1/NO pathway may be particularly important in early
stages or mild forms of the disease, where the IA vascular response
plays a predominant role in colitis progression. Finally, our data
from IBD-affected patients showing elevated MT1-MMP expression
in the inflamed vasculature and elevated serum TSP1 suggest their
potential usefulness as surrogate biomarkers of disease activity.
Figure 9. Working model of the role of MT1-MMP/TSP1/nitric oxide axis in IA during colitis.
The scheme depicts the role that endothelial cell MT1-MMP (left) exerts in IA during colitis by processing TSP1 and binding of the generated TSP1 C-terminal fragment to
CD47/avb3 integrin, thus inducing nitric oxide production. This signaling cascade ultimately leads to arteriole vasodilation and endothelial cell intussusceptive remodeling in
the capillary plexus of the inflamed intestinal mucosa. WhenMT1-MMP is absent from endothelial cells (right), this pathway is impaired, IA reduced, and colitis ameliorated.
EC, endothelial cell; P, pericyte; FB, fibroblast; Col, collagen.
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Materials and Methods
Animals
C57BL/6 wild-type mice were purchased from Charles River, and
MT1-MMP (Mmp14)-lacZ reporter mice were as previously reported
(Yana et al, 2007). Mmp14loxP/loxP mice (Gutierrez-Fernandez et al,
2015) were crossed with Cdh5-CreERT2 mice (kindly provided by
Prof. Adams’ laboratory; Wang et al, 2010) to generate Mmp14loxP/
loxP;Cdh5-CreERT2/+ mice (MT1iDEC mice). Mice at 8–20 weeks old
were injected intraperitoneally with 1 mg per mouse of 4-hydroxy-
tamoxifen (4-OHT) on five consecutive days to induce endothelial
cell-specific deletion of MT1-MMP (Monvoisin et al, 2006). Mice
were housed and all animal experiments performed under specific
pathogen-free conditions at the Animal facility of Centro Nacional
de Investigaciones Cardiovasculares Carlos III (CNIC), and in strict
accordance with the institutional guidelines. Mice were kept under
a 12-h light/dark cycle (lights on from 07:00 to 19:00 h) and fed
ad libitum with standard chow diet (2108 Teklad Global, Harlan
Interfauna Iberica S.L.). Mice were genotyped by tail DNA PCR using
the following primers: for the MT1-flox recombination, 50-CCCTGGG
TCAACTACAGCA-30 and 50-TTTGTGGGTGACCCTGACTTG-30; for
LacZ, 50-ATCGTGCGGTGGTTGAA-30 and 50-TGCTGACGGTTAACGC
CTCG-30; and for Cre, 50-AGGTGTAGAGAAGGCACTTAGC-30 and 50-
CTAATCGCCATCTTCCAGCAGG-30.
Mouse experimental colitis
Experimental colitis was induced in 8- to 20-week-old mice by
supplying 1% dextran sodium sulfate (DSS) (MP Biomedicals,
0216011010) dissolved in drinking water ad libitum for 3 or 7 days.
Daily monitoring included measuring body weight and calculating
disease activity index (DAI). The baseline colitis on day 0 was
scored as 0. Subsequent weight loss of 1–5% was scored as 1, 5–
10% as 2, 10–20% as 3, and more than 20% as 4. For stool consis-
tency, normal, well-formed pellets were scored as 0, semi-formed
pellets not adhering to the anus were scored as 2, and liquid stools
adhering to the anus were scored as 4. Similarly, no bleeding was
assigned a score of 0, positive blood detection in the stool was
scored as 2 (detected by hemoFEC, Cobas, 10243744), and gross
rectal bleeding was scored as 4. At the end of the DSS exposure
period, the whole colon was removed and cleaned with PBS. The
most distal portion was fixed in 4% PFA overnight and then used
directly for whole-mount staining, processed, and embedded in
paraffin or frozen in OCT for histological analysis. The remaining
part of the colon was homogenized for protein and RNA extraction.
The anti-MT1-MMP antibody LEM-2/15 and the E123CaG-1 TSP1
fragment were administered to mice by intraperitoneal injection at
3 mg/kg and 1 lg, respectively, on day 0 and day 2 during the
3 days of 1% DSS treatment. No statistical methods were used to
pre-estimate the animal sample size, and mice were randomly allo-
cated to experimental groups. Investigators were not blinded during
the analysis of mouse samples.
Lentiviral infection
The full-length MT1-MMP sequence (FL) or mutated versions to
disable catalytic activity (E240A, EA) or block signaling activity
(Y573F, YF) were cloned into the SFFV-IRES-GFP lentiviral back-
bone. Lentiviruses expressing Mock, MT1-MMP FL, EA, or YF were
prepared and titered as previously described (Martin-Alonso et al,
2015). Lentivirus solution (100 ll) was injected intravenously into
the jugular vein of adult MT1iDEC mice at 1 × 107 pfu/ml. Mice were
administered 1% DSS for 3 days and then sacrificed, and colons
were processed for whole-mount staining.
Subcutaneous pump implantation
MT1-MMPf/f control mice were anesthetized with isoflurane and
implanted with subcutaneous micro-osmotic pumps (Alzet, model
10003D) charged with 10 mg/100 ll of the peptides GDGRGDACK or
GDGRADACK. Pumps released ~1 ll/h (100 lg/h), equivalent to
2.4 mg/mouse/day. Mice were administered 1% DSS for 3 days and
then sacrificed, and colons were processed for whole-mount staining.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased
from Lonza (BioWhittaker, CC-2519) and cultured on 0.5% gelatin-
coated plates (unless otherwise indicated) in medium 199 supple-
mented with 20% FBS, 100 U/ml penicillin (Lonza), 100 lg/ml
streptomycin (Lonza), 2 mM L-glutamine (Lonza), 10 mM HEPES
(Lonza), and ECGS/H (Promocell, C-30120). Cells were used up to
passage 5. Mouse aortic endothelial cells (MAEC) were obtained
from aortas of 4-week-old mice. Briefly, after fat removal under a
microscope, aortas were incubated for 5 min at 37°C in collagenase
solution (collagenase type I, 3.33 mg/ml, Worthington, LS004194),
thus allowing removal of the adventitia with forceps. The aortas were
then cut into small pieces (1–2 mm), and a cell suspension was
obtained by incubation for 45 min at 37°C in 6 mg/ml type I collage-
nase and 2.5 mg/ml elastase (Worthington, LS002290) diluted in
DMEM. Once EC colonies were visible, they were subjected to two
rounds of positive selection with anti-ICAM2 and magnetic beads.
MAEC were cultured on 0.2% gelatin-coated plates in DMEM/F12
medium supplemented with 20% FBS, 100 U/ml penicillin (Lonza),
100 lg/ml streptomycin (Lonza), 2 mM L-glutamine (Lonza), 10 mM
HEPES (Lonza), and ECGS/H (Promocell, C-30120).
MT1-MMP siRNA silencing
HUVEC were transfected twice with 10 nM MT1-MMP-specific
siRNAs [Ambion, Thermo Fisher Scientific, MT1-ARNi#1, 8877
(4390824); MT1-ARNi#2, 8879 (4390824)] or control scramble siRNA
[Ambion, Thermo Fisher Scientific, Control No. 1 (4390843)] using
RNAiMAX Lipofectamine (Thermo Fisher Scientific, 13778030).
Downregulation was confirmed by qPCR and Western blot.
Vascular perfusion and permeability assays
For vascular perfusion analysis, mice received intravenous injec-
tions of 100 ll of biotinylated or FITC-GSL I Isolectin B4 (Vector
Labs, B1205 and FL-1201, respectively) 20 min before sacrifice.
Mice were perfused under constant pressure with cold PBS, and
colon samples were extracted and processed for whole-mount stain-
ing. Vascular perfusion was quantified as the percentage of the
CD31-positive vascular volume containing an IB4 signal.
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For vascular permeability analysis, mice received intravenous
injections of 100 ll of 0.5 mg/ml (71.5 lM) Dextran-TRITC 70 KD
(Invitrogen, D1819) 20 min before sacrifice. Colon samples were
extracted and frozen in OCT, and 30-lm-thick sections were
immunostained and visualized.
Quantitative real-time PCR
RNA was extracted with the RNeasy Plus Micro Kit (Qiagen, 74034).
cDNA was synthesized using the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, 4368814). Quantitative PCR was
performed using Power SYBR Green PCR Master Mix (Applied
Biosystems, 4367659) following the manufacturer’s protocol. The
primers used in qPCR are listed in Appendix Table S2. GAPDH,
36b4, and TBP were used as internal expression controls. The
results (CNRQ; calibrated normalized relative quantity) were
analyzed with qbase Plus software (Biogazelle, Gent, Belgium).
Western blot
Cells were lysed in RIPA buffer supplemented with protease and
phosphatase inhibitors. Protein samples were separated by 8% SDS–
PAGE, transferred to nitrocellulose membranes, blocked with 5%
BSA, and incubated sequentially with primary and horseradish perox-
idase (HRP)-conjugated secondary antibodies, with washes. The
primary antibodies used were anti-MT1-MMP (LEM-2/15) (Galvez
et al, 2001), anti-eNOS (BD Bioscience, 610297), anti-GFP (Abcam,
ab13970), anti-GAPDH (Sigma-Aldrich, G9545), and anti-b-actin
(Sigma-Aldrich, A5441). All primary antibodies were used at a dilu-
tion of 1:1,000. The secondary antibodies used were HRP goat anti-
mouse and HRP goat anti-rabbit (Jackson), and bound secondary
antibodies were visualized with Luminata Classico Western HRP
Substrate (Millipore, WBLUC0500) in ImageQuant LAS 4000 (GE
Healthcare Life Sciences, Massachusetts, USA). Western blots were
quantified using ImageJ software (https://imagej.nih.gov/ij/).
In vitro digestion assay
Human TSP1 purified from plasma (a gift from Dr. G. Taraboletti,
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo,
Italy) was incubated with increasing amounts of the catalytic
domain of human recombinant MMP14 (hrMMP14, ref. 475935;
Calbiochem, San Diego, USA) in digestion buffer (50 mM Tris–HCl,
10 mM CaCl2, 80 mM NaCl [pH 7.4]) for 2 h at 37°C. Samples were
separated by 10% SDS–PAGE and transferred to nitrocellulose
membranes (Bio-Rad, 45 lm). Full-length TSP1 and fragments were
detected with an anti-TSP1 antibody recognizing an epitope nearby
the N-terminus (Lee et al, 2006). An anti-rabbit HRP secondary anti-
body (Jackson) was used and the bound proteins developed with
Luminata Classico Western HRP Substrate (Millipore, WBLUC0500)
in ImageQuant LAS 4000 (GE Healthcare Life Sciences, Massachu-
setts, USA).
Whole-mount staining
For cremaster muscle, anesthetized mice were intravenously
injected with 100 ll of 100 lM acetylcholine 15 min before sacrifice
and with 100 ll of 100 lM sodium 2-(N,N-diethylamino)-
diazenolate-2-oxide (DEANO) 5 min before sacrifice; saline was
used as a control for both injections. For VEGF administration to the
distal colon, 20 ng of VEGF (PeproTech, 450-32) in a final volume
of 50 ll was delivered into anesthetized mice via a rectal cannula,
10 min before sacrifice. Cremaster muscle or distal colon was then
removed, cleaned, flat-mounted, and fixed with 4% PFA overnight
at 4°C. Mouse and human whole-mount samples were blocked and
permeabilized in blocking solution (PBS 5% BSA, 5% normal goat
serum, and 0.3% Triton X-100). Primary antibodies were diluted
1:100 in blocking solution, and samples were incubated on a shaker
at 4°C overnight. Vessels were stained with anti-CD31 (Millipore,
MAB1398Z), anti-ICAM2 (BD Pharmingen, 553325), and anti-ERG
647 (Abcam, ab196149). The following day, the samples were
washed 3 × 1 h in PBS and 0.1% Triton X-100 and incubated over-
night at 4°C with the appropriate secondary fluorescent antibodies
(goat anti-Armenian hamster IgG, anti-mouse IgG, anti-rabbit IgG,
or anti-rat IgG, all from Jackson ImmunoResearch) and Hoechst
33342 (Invitrogen, H1399). The next day, samples were washed
3 × 1 h in PBS and 0.1% Triton X-100 and mounted in glycerol.
Fluorescence microscopy images were acquired with a Zeiss LSM
700 confocal microscope at 21–23°C using Plan-Apochromat,
25 × 0.8 or 63× glycerol DIC M27, and z-stacks were captured every
1.5 or 1 lm, respectively. Confocal images were imported into
Imaris (version 7.7.2; Bitplane AG, Switzerland) to obtain a precise
3D reconstruction generated by the program’s iso-surface rendering
function of this software. In 3D images of the mucosal vasculature,
we evaluated vascular volume, intussusception events (holes, loops,
and duplications), and vascular perfusion, and in 3D images of the
cremaster muscle, capillary diameters were quantitated. Intercapil-
lary angles in the mucosa vascular plexus were measured by ImageJ
software. Capillary diameters in CD31-stained whole-mount colons
after VEGF rectal administration were quantified by an ImageJ ad-
hoc plugin (http://adm.irbbarcelona.org/image-j-fiji#TOC-Blood-ve
ssel-segmentation-and-network-analysis).
Second-harmonic generation multi-photon microscopy
Autofluorescence of fibrillar collagen (425- to 465-nm filter) was
visualized in flat-mounted fixed colon from MT1f/f and MT1iDEC
mice with a Zeiss LSM 780 microscope coupled to a Spectra-Physics
Mai Tai DS Laser, using an 800 nm excitation wavelength, which
resulted in the SHG signal detectable at 400 nm (emission fluores-
cence range 388–408 nm).
Endothelial cell immunofluorescence staining
Confluent ECs on glass coated with 1% gelatin were fixed with 4%
PFA during 8 min at RT. The cells were stained with anti-MT1-MMP
(LEM-2/15) and anti-TSP1 (Thermo Fisher, MA5-13398) primary
antibodies diluted 1:100. Cells were incubated with appropriate
secondary fluorescent antibodies (anti-mouse IgG, anti-rabbit
IgG from Jackson ImmunoResearch), phalloidin FITC (Life Tech-
nologies, F432), and Hoechst 33342 (Invitrogen, H1399) for 30 min
at 37°C. Fluorescence microscopy images were acquired with a Zeiss
LSM 700 confocal microscope at 21–23°C using Plan-Apochromat,
40 × 0.8 oil DIC M27, and z-stacks were captured every 1 lm.
Images were analyzed using ImageJ software (https://imagej.
nih.gov/ij/).
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Cell sorting
Freshly isolated mouse lung endothelial cells (MLECs) were
obtained from lungs as described (Oblander et al, 2005). Red blood
cells were removed by incubating the lung cell suspension for 5 min
in ACK buffer (150 mM NH4Cl, 0.1 mM Na2EDTA, 10 mM KHCO3,
pH = 7.4). The cells were then resuspended in sorting buffer
(PBS + 1% FBS + 10 mM HEPES) and incubated for 10 min at 4°C
with an Fc-block anti-CD16/CD32 mAb (Pharmingen) to block non-
antigen-specific binding of immunoglobulins to the Fcc receptors.
This was followed by staining with Alexa Fluor 488-conjugated anti-
mouse CD31 (Mec13.3) and V405-conjugated anti-mouse CD45.1
(all from BD Bioscience Pharmingen). The endothelial cell popula-
tion defined as CD31+/CD45 was sorted in a Synergy 4L Cell
Sorter (Sony Biotechnology Inc.), and MT1-MMP deletion efficiency
was analyzed by qPCR.
Enzyme-linked immunosorbent assay
C57BL/6 mice were administered 1% DSS for 7 days; blood was
collected by cardiac puncture, and serum was separated and stored
at 80°C. Soluble TSP1 was measured in serum by enzyme-linked
immunosorbent assay (Mouse TSP1 ELISA kit; Cusabio, CSB-
E08765m). Soluble TSP1 in serum from human control individuals
and IBD patients was measured by ELISA (Human TSP1 DuoSet
ELISA; R&D Systems, DY3074). Mean optical density (OD) at
450 nm was calculated from triplicate readings per sample, and OD
values at 570 nm were subtracted to correct for optical imperfec-
tions in the plate reading. A 4-parameter logistic (4-PL) curve fit
was generated using Benchmark Plus Microplate Spectrophotometer
(BIO-RAD) coupled to Microplate Manager 5.2.1.
Colon immunofluorescence staining
Paraffin-embedded colonic mouse experimental colitis samples were
cut into 5-lm sections, deparaffinized, hydrated through an alcohol
series of decreasing concentration, and treated with sodium citrate
buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) for 20 min
at 95°C and then cooled for 2 h at room temperature for antigen
retrieval. Sections were permeabilized with PBS containing 0.3%
Triton X-100 for 10 min at room temperature and blocked with
Image-iTTM FX signal enhancer (Invitrogen, 36933) for 30 min at
room temperature and with blocking buffer (PBS with 5% BSA and
5% goat serum) for 1 h at room temperature. Sections were incu-
bated with the following primary antibodies overnight at 4°C in
blocking buffer: anti-CD31 (DIANOVA, DIA310) anti-MT1-MMP
(LEM-2/15) and anti-TSP1 (provided by Dr M. L. Iruela-Arispe,
University of California, Los Angeles, CA, USA, 10 lg/ml). Subse-
quently, samples were washed with PBS and 0.1% Triton X-100 and
incubated for 2 h at room temperature with the corresponding
conjugated secondary antibodies and Hoechst 33342. Samples were
mounted in Fluoromount-G imaging medium (4958-02, Affymetrix
eBioscience).
Samples included in OCT were permeabilized and blocked in
PBS containing 0.3% Triton X-100, 5% BSA, 5% goat serum, and
anti-CD16/CD32 (clone 24g2, 1:100) for 1 h at room temperature.
Samples were then incubated overnight at 4°C with anti-CD11b
Alexa 647 (clone M1/70, eBiosciences, 51-0112-82), anti-Erg, anti-b-
galactosidase, and anti-ICAM2. Samples were then incubated with
the corresponding secondary antibodies and Hoechst 33342 for 2 h
at room temperature. Finally, samples were mounted in Fluoro-
mount-G, and images were acquired with a Zeiss LSM 700 confocal
microscope fitted with a 25× objective and processed and quantified
using ImageJ software.
Nitric oxide production
Confluent ECs were seeded in 96-well glass plates coated with 1%
gelatin and cultured in EGM2 (Promocell, C-22111). The cells were
incubated with 2.5 lM DAF-FM diacetate (Life Technologies,
D23842) for 30 min at 37°C and washed with PBS. The DAF-FM flu-
orescence signal was visualized with a Zeiss LSM 700 confocal
microscope (Plan-Apochromat 40 × 1.3 Oil DIC M27), and mean flu-
orescence intensity (MFI) at single-cell level was analyzed with
ImageJ software. HUVEC were treated for 24 h with antibodies to
MT1-MMP (LEM-2/15), integrin av [anti-av integrins ABA 6D1
(Yanez-Mo et al, 1998)], or CD47 (Abcam, ab3283), with a range of
concentrations of the peptides RGDS, RADS, cilengitide, TSP1
nonamer GDGRGDACK, or the control GDGRADACK, or with
human full-length TSP1 or the human recombinant TSP1 fragment
E123GaC-1.
Intravital microscopy in the cremaster muscle
For the analysis of arteriolar vasodilation, mice were anesthetized,
and the cremaster muscle was isolated and exposed on the micro-
scope plate as described (Rius & Sanz, 2015). Mice were injected
with 100 ll of 100 lM acetylcholine, and arterioles were recorded
for at least 15 min using a Leica DM6000-FS intravital microscope
fitted with an Apo 40× NA 1.0 water-immersion objective and linked
to a DFC350-FX camera. LASAF software was used for image acqui-
sition and processing.
In silico modeling of MT1-MMP dimer
The MT1-MMP monomer was modeled by submitting the Fasta
sequence of mature human MT1-MMP protein (UniProt ID:
P50281, residues 112–582) to a local implementation of I-Tasser
software suite v4.4 (Yang et al, 2015) for threading modeling
with homology. The selected model was that with minimal energy
and correct folding (best structural alignment to templates; PDB
ID: 1BQQ for catalytic domain and 3C7X for hemopexin-like
domain). In this model, the transmembrane domain (TM) is
buried in the protein core. To fix this, this region (transmem-
brane plus C-term, TMIC) was extracted from the model, angles
were fixed according to the predicted secondary structure, and a
refinement cycle was performed using the relax tool (Nivon et al,
2013; Conway et al, 2014) in Rosetta suite v3.5 release
2015.38.58158 (www.rosettacommons.org). The best model for
TMIC (lower energy and best stability) was selected and aligned
with the previous MT1-MMP model, and the new model
composed of MT1-MMP without TMIC domains and the new
TMIC model was used as the template; the gap between them
was closed using the loopmodel tool (Mandell & Kortemme, 2009;
Stein & Kortemme, 2013) in Rosetta suite. The most stable model
was selected as the final model for the MT1-MMP monomer. To
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model dimeric MT1-MMP, two of these monomers were posi-
tioned according to the published MT1-MMP dimer interface
using PyMOL v1.8 (www.pymol.org), and the new dimer model
was used as the initial template. A new PDB file was generated
for the model, in which the membrane protein structure is
transformed into PDB coordinates (with the z-axis normal to the
membrane) using the PPM server (http://opm.phar.umich.edu/se
rver.php). A full spanfile was generated from the PDB structure
using the spanfile_from_pdb application in the membrane frame-
work in Rosetta suite v3.5 release 2015.38.58158. An initial relax
cycle was performed using the relax application in Rosetta suite
to minimize energy and clashes using the initial template and the
full spanfile (Conway et al, 2014). The lowest scoring refined
model (lowest energy) was selected as the input model, and a
new dimer model was generated using the mp_dock application
in the Rosetta suite membrane framework (Alford et al, 2015).
All models with TM embedded in the membrane clustered
together. The best model, with lowest energy, was selected as the
final dimer. This homodimer meets the previously described bind-
ing interface constraints, with docking via the hemopexin-like
domains, and has quasi-C2 symmetry. We next positioned the
MT1-MMP dimer model together with the reported crystal struc-
ture of the TSP1 type 1 repeat (PDB ID: 1LSL) using PyMOL and
evaluated the global topography and accessibility of the complex.
Statistics
Protein expression on Western blots was quantified densitometri-
cally using ImageJ software (NIH, Bethesda, USA) and normalized
to the corresponding loading control. Data were tested for normal
distribution by D’Agostino–Pearson test and compared with non-
parametric or parametric statistical tests as appropriate (see figure
legends for details). Graphs were prepared and statistical analysis
performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla,
USA). Data are presented as mean  standard error of the mean
(SEM). Differences were considered significant at *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval
Animal procedures were approved by the Committee on the
Ethics of Animal Experiments of the CNIC (Permit Number:
CNIC-01/13) and by the corresponding legal authority of the
local government “Comunidad Autónoma” of Madrid (Permit
Number: PROEX 34/13). Animal studies were conformed to
directive 2010/63EU and recommendation 2007/526/EC regarding
the protection of animals used for experimental and other scien-
tific purposes, enforced in Spanish law under RD1201/2005.
Human samples were obtained with informed consent after ethi-
cal approval by the Hospital de La Princesa Ethics Committee.
Informed consent was obtained from all subjects, and the experi-
ments conformed to the principles set out in the WMA Declara-
tion of Helsinki and the Department of Health and Human
Services Belmont Report.
Expanded View for this article is available online.
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The paper explained
Problem
Human inflammatory bowel disease (IBD) is a chronic inflammatory
disease of the intestine comprising ulcerative colitis and Crohn’s
disease and characterized by phases of remission and relapse. IBD is a
multifactorial disease featuring a primary defect in intestinal epithelial
barrier integrity and an exacerbated immune response to the micro-
biota. The use of immunomodulators, new biologics, and small mole-
cules has improved IBD treatment in the recent years, but non-
responder patients and the unpredicted nature of relapses make
necessary to expand our knowledge about other processes influencing
IBD pathophysiology. Colitis progression seems to involve angiogene-
sis, the formation of new vessels from pre-existing ones, which is
regarded as a potential therapeutic target but with limited success in
animal models. A better understanding of the molecular pathways
behind colitis-associated angiogenesis will help designing more effi-
cient and tailor-based therapies for this complex disease.
Results
In this study, we implemented confocal microscopy and 3D image
reconstruction tools to investigate intussusceptive (or splitting) angio-
genesis (IA), a poorly characterized mode of angiogenesis, in a mouse
model of IBD. After induction of mild colitis, we detected an increased
number of vascular events, all hallmarks of IA. We next explored the
role of the matrix metalloproteinase MT1-MMP in IA and we demon-
strated that the selective absence of MT1-MMP from endothelial cells
decreased IA events and led to improved vascular perfusion, milder
clinical score, and better-preserved intestine morphology during
mouse colitis.
Vasodilation is an obliged prerequisite to IA, and we demonstrated
that endothelial MT1-MMP absence decreased capillary vasodilation
induced by VEGF in the intestine and by acetylcholine in the muscle.
We showed in vivo and in vitro that MT1-MMP catalytic activity was
required for nitric oxide production and for the induction of IA. In vitro
digestion assays, in silico protein modeling, and endothelial cell culture
identified the cleavage of the matricellular protein thrombospondin-1
(TSP1) by MT1-MMP as responsible for nitric oxide production. Finally,
we found higher levels of TSP1 in serum from low active IBD patients,
and we reduced IA during mouse colitis progression via anti-MT1-MMP
antibody injection or delivery of a blocking TSP1 peptide.
Impact
We propose that our findings have both diagnostic and therapeutic
clinical impacts for patients with IBD. Indeed, our data from IBD-
affected patients suggest that MT1-MMP and TSP1 could serve as surro-
gate biomarkers of disease activity. Moreover, our findings identify the
MT1-MMP/TSP1/avb3 integrin/nitric oxide pathway as a novel actor in
IA whose targeting ameliorates colitis progression. We have demon-
strated this therapeutic application by blocking this axis with anti-MT1-
MMP inhibitory antibodies, and through selective competition of TSP1
binding to avb3 integrin by continuous peptide delivery. Since we found
elevated serum TSP1 in patients with low active colitis and MT1-MMP
endothelial deletion protected mainly from mild colitis, these therapeu-
tic options may be of special value in early stages or mild forms of IBD.
Finally, the in silico docking of the TSP1 cleavage sites with MT1-MMP
could lead to small-molecule screening and to new cell-specific strate-
gies involving peptide-directed delivery, nanoparticles, or other modes
of tissue-tailored therapeutic intervention.
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